Would you like to learn more about the Biopharmaceutical Industry and:
1). Career paths for neurologists in industry
2). Learn personal experiences from the guest speaker's path from academia - via NINDS - to industry
3). Gain insights and practical advice on successfully transitioning to the biopharmaceutical industry
Then please join us as we host Dr. Dietrich Haubenberger, who will lead this discussion by addressing a variety of talking points geared towards this very topic. Dr. Dietrich Haubenberger received his medical and postgraduate training as neurologist at the Medical University of Vienna, followed by a post-doctoral fellowship at the National Institutes of Health in Bethesda, MD, conducting clinical research projects on genetics, disease mechanisms, outcome measure development, as well as clinical trials involving novel therapies for neurological movement disorders including tremor, dystonia, and Parkinson’s disease. After returning to the Medical University of Vienna in 2011, Dr. Haubenberger lead the Clinical Neurophysiology service at the Dept. of Neurology, received his Habilitation, and was promoted to Associate Professor in Neurology. In 2014, Dr. Haubenberger returned back to NIH (NINDS) as Director of the NINDS Clinical Trials Unit and Assistant Clinical Director for Clinical Research, where he oversaw over 100 ongoing neurological clinical research studies at the world’s largest research hospital, the NIH Clinical Center, including emerging modalities such as gene therapy and non-invasive brain stimulation. In 2019, Dr. Haubenberger transitioned to Neurocrine Biosciences, a biopharmaceutical company in San Diego, CA. As Executive Medical Director for Clinical Development, Dr. Haubenberger is the clinical lead in early and late-stage drug development programs for neurological diseases with high unmet need for novel therapeutics and is leading translational biomarkers group. Dr. Haubenberger lead the development program for valbenazine in the treatment of Chorea associated with Huntington’s Disease, which resulted in a New Drug Application approval by the U.S. Food and Drug Administration (FDA) in August 2023. Further, Dr. Haubenberger holds a Voluntary Associate Clinical Professor position at the Dept. of Neurosciences, University of California San Diego (UCSD), to teach junior faculty as well as trainees in clinical neurophysiology of movement disorders, and support research projects of trainees and faculty at UCSD.
________________________________________________________________________________
Microsoft Teams meeting
Join on your computer, mobile app or room device
Click here to join the meeting
Meeting ID: 219 640 141 863
Passcode: grbKtq
Download Teams | Join on the web
Or call in (audio only)
+1 240-800-7959,,810701356# United States, Bethesda
Phone Conference ID: 810 701 356#
Find a local number | Reset PIN
_________________________
CONTACTS
Name: Sandi Bonifant
Email: bonifans@ninds.nih.gov
Phone: 301-451-0867
Or
Name: Katy Finnell
Email: finnellk@nih.gov
Phone: 301-594-3359